Silvia Brugiapaglia

The dark side of immunotherapy: pancreatic cancer

F. Novelli, P. Cappello, C. Roux, 2020, Cancer drug resistance.

The Glycolytic Pathway as a Target for Novel Onco-Immunology Therapies in Pancreatic Cancer

C. Curcio, F. Novelli, P. Cappello, 2021, Molecules.

1318 A next generation DNA vaccine coding for the immunodominant sequence of alpha-enolase with enhanced ability to induce effector T cell responses to cure pancreatic cancer

C. Curcio, F. Novelli, M. Berrino, 2022, Regular and Young Investigator Award Abstracts.

1429 Immune receptor PIRB deletion impacts pancreatic cancer growth and anti-tumor immune response

T. Takai, C. Curcio, F. Novelli, 2022, Regular and Young Investigator Award Abstracts.

HLA‐DPB1*13:01 associates with enhanced, and KIR2DS4*001 with diminished protection from developing severe COVID‐19

Wesley M. Marin, C. Fallerini, T. D. Farias, 2023, HLA.

IL-1β^+ macrophages fuel pathogenic inflammation in pancreatic cancer

F. Ginhoux, L. Ng, L. Naldini, 2023, Nature.

PI3Kγ inhibition combined with DNA vaccination unleashes a B-cell-dependent antitumor immunity that hampers pancreatic cancer

P. Cappello, J. Varner, C. Roux, 2024, Journal of experimental & clinical cancer research : CR.